Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estetrol in advanced ER+ breast cancer
NCT02718144Phase 2Completed
- Sponsor
- Pantarhei Oncology
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estetrol in breast cancer, sponsored by Pantarhei Oncology. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Jun 2017; status: completed.
02
Drugs
estetrol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02718144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718144.